⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

モデル
薬剤
インサイト

Company

CROパートナー
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Wegovy (Semaglutide) | 加速させる、線維化研究を

Home/Drugs/Wegovy

Wegovy

Semaglutide

Approved (MASH - FDA 2025)

Sponsor: Novo Nordisk

Indication: MASH / Obesity

Mechanism of Action

GLP-1 Receptor Agonist

Target: GLP-1

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

ACTIVE_NOT_RECRUITINGNCT06467604

CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users

Org:University of California, Davis

COMPLETED

Relevant Publications (PubMed)

Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial.

Neves JS, Leite AR, Vale C et al.

Diabetologia2025 Dec 19

Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.

Eisa N, Barood O

Endocr Pract2025 Dec 17

GLP-1 Receptor Agonist-Associated Slimmer's Palsy: Implications for the Peripheral Nerve Surgeon.

Dhupati P, Kisiel SC, Unadkat K et al.

Ann Plast Surg2026 Jan 1

Effect of semaglutide add-on therapy for people living with type 1 diabetes and excess weight.

Validated Models

This drug has been validated in the following preclinical models:

NCT02172313

Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects

Phase:PHASE1Org:Novo Nordisk A/S

COMPLETEDNCT02557620

Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly

Phase:PHASE1Org:Novo Nordisk A/S

COMPLETEDNCT05920889

Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies

Phase:PHASE2Org:Chinese University of Hong Kong

COMPLETEDNCT05766709

A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations

Phase:PHASE1Org:Novo Nordisk A/S

View all trials on ClinicalTrials.gov

Minsky NC, Olshanskiy D, Aharon-Hananel G

Diabetes Obes Metab2025 Dec 19

Injectable drugs for weight management.

Yates N, South TL

Aust Prescr2025 Dec

View more on PubMed